<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098613</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1511901</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Coagulation functions and factors correlated with central nervous system infection in herpes zoster patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Yanrong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Jing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Huili</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sun</surname><given-names>Zeyu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1480753/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pan</surname><given-names>Dongli</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1454829/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yan</surname><given-names>Yongxing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2869559/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Neurology, Hangzhou Third People&#x02019;s Hospital</institution>, <addr-line>Hangzhou, Zhejiang</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>State key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine</institution>, <addr-line>Hangzhou, Zhejiang</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Medical Microbiology and Parasitology, Zhejiang University School of Medicine</institution>, <addr-line>Hangzhou, Zhejiang</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Julie Olson, University of Minnesota Twin Cities, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Charles Grose, The University of Iowa, United States</p><p>Sofia Jord&#x000e3;o, Hospital Pedro Hispano, Portugal</p></fn><corresp id="fn001">*Correspondence: Yongxing Yan, <email xlink:href="mailto:yyxing20@126.com">yyxing20@126.com</email>; Dongli Pan, <email xlink:href="mailto:pandongli@zju.edu.cn">pandongli@zju.edu.cn</email>; Zeyu Sun, <email xlink:href="mailto:zeyusun@zju.edu.cn">zeyusun@zju.edu.cn</email>
</corresp><fn fn-type="other" id="fn003"><p>&#x02020;ORCID: Dongli Pan, <uri xlink:href="https://orcid.org/0000-0002-0421-6242">orcid.org/0000-0002-0421-6242</uri>
</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1511901</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Yuan, Gu, Liu, Wang, Sun, Pan and Yan</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Yuan, Gu, Liu, Wang, Sun, Pan and Yan</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Reports on central nervous system (CNS) infection caused by varicella-zoster virus (VZV) reactivation are increasing, but its pathogenesis remains unclear, which causes delayed diagnosis and treatment. Some studies suggested that hypercoagulability is involved in the pathogenesis of CNS infection of VZV. This study investigated the coagulation parameters of herpes zoster (HZ) and their correlations with the VZV-related CNS infection, and provided a reference for the early diagnosis and treatment.</p></sec><sec><title>Methods</title><p>We selected 123 consecutive patients, including 95 HZ cases and 28 VZV meningitis (VZVM) cases hospitalized due to HZ. Forty-seven patients who underwent physical examination in our hospital were used as Health controls (HCs) group. The coagulation parameters of the three groups were measured and compared, and the correlation between coagulation function parameters and CNS infection was analyzed by Logistic regression. the expression of coagulation factor in cerebrospinal fluid (CSF) proteomics of 28 VZVM patients and 11 HZ patients were analyzed.</p></sec><sec><title>Results</title><p>Compared with HCs group, plasma Fibrinogen (Fib) and D-dimer (DD) levels in HZ and VZVM group were significantly increased (P &#x0003c;0.01), while there were no significant differences in other parameters (P &#x0003e; 0.05). There was also no significant difference in the levels of coagulation parameters between the HZ and VZVM groups (P &#x0003e; 0.05). Proteomic analysis of CSF revealed that there was no difference in the expression levels of Fib, Antithrombin III (AT-III), and coagulation factors VII, IX, X, XI in the HZ and VZVM patients (P &#x0003e; 0.05). The expression levels of coagulation factors XII and XIIIa were higher in VZVM patients than those in HZ patients (P &#x0003c; 0.05 and P &#x0003c; 0.01, respectively).</p></sec><sec><title>Conclusion</title><p>In HZ and VZVM patients, a hypercoagulable state was observed with increased Fib and DD levels. However, hypercoagulation was not a risk factor for CNS infection, and there was no significant correlation between the elevated level and the severity of disease.</p></sec></abstract><kwd-group><kwd>herpes zoster</kwd><kwd>central nervous system</kwd><kwd>varicella-zoster virus</kwd><kwd>coagulation function</kwd><kwd>infection</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Hangzhou Municipal Health and Family Planning Commission
</institution><institution-id institution-id-type="doi">10.13039/100015807</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. We acknowledge the work was supported by grants from the Key Projects of Hangzhou Health Science and Technology Plan (ZD20210010), the Guidance Project of Hangzhou Science Plan (agriculture and social development) (20211231Y034), the Construction Fund of Medical Key Disciplines of Hangzhou (2020-2024), National Key Research and Development Program (2022YFA1303801), Chinese National Natural Science Foundation (U20A200603, 82370612), Independent Foundation of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases (zz202311).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="42"/><page-count count="8"/><word-count count="3213"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Viral Immunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Herpes zoster (HZ) is a skin infectious disease caused by the reactivation of latent varicella-zoster virus (VZV) in the human body. It is characterized by vesicles and rashes of the skin in the neurodistributive area, often accompanied by pain (<xref rid="B1" ref-type="bibr">1</xref>). Although HZ is a self-limiting skin disease, it can cause neurological complications such as postherpetic neuralgia (PHN) and cranial neuritis. In severe cases, central nervous system (CNS) infection can occur, such as meningitis, encephalitis, myelitis, cerebellar encephalitis and other complications, and even lead to serious complications such as death, increasing the burden on families and society (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>). However, early identification and treatment of HZ patients with CNS infection mostly achieved good prognosis. Therefore, the early diagnosis and treatment is extremely important.</p><p>However, the mechanism of VZV reactivation leading to CNS infection has not been fully clarified, which may be related to direct viral infection, sustained inflammatory response, vasculitis, hypercoagulability, etc. Some studies have also found that viremia occurs in approximately 50% of the cases of HZ in immunocompetent adults, which is believed to be an important component of the pathogenesis of CNS complications in HZ (<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>). Currently, vasculitis is postulated as the most likely pathophysiological mechanism of VZV-related CNS infection (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>). Vasculitis can cause coagulation dysfunction, thrombosis, and vice versa. Previous studies have also found that virus infection can activate hemolytic fibrinolytic system, lead to changes in coagulation function, microthrombus, and even pulmonary embolism, disseminated intravascular coagulation (DIC) and other life-threatening complications (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Human type 3 herpesvirus VZV can cause chickenpox and shingles after infection. However, it is still unclear whether the changes in coagulation functions in HZ patients and the changes in the plasma coagulation function parameters are risk factors for VZV-related CNS infection. Although some scholars believe that hypercoagulability is involved in the pathophysiological mechanism of VZV-related CNS infections, there are few studies on coagulation function in those patients. Therefore, this study examined coagulation factors in HZ and VZVM patients to assess their correlation with CNS infection, aiming to provide initial evidence of coagulation dysfunction&#x02019;s role in HZ-CNS infection and support early diagnosis and treatment.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2_1"><title>Subjects</title><p>A total of 123 consecutive patients with shingles who were admitted to our hospital from January 2020 to January 2023 were selected, including 28 VZV meningitis (VZVM) cases and 95 HZ cases according to clinical manifestations of shingles patients and routine cerebrospinal fluid, biochemical and VZV DNA detection, and 47 health controls (HCs) from physical examination program in our hospital. Our study has been approved by the Ethics Committee of Hangzhou Third people&#x02019;s Hospital (NO.2021KA013). All procedures were conducted in accordance with the Helsinki Declaration.</p><p>Inclusion criteria: 1). Age &#x0003e;18; 2). All patients had skin erythema, vesicles, blisters and other clinical manifestations, which met the diagnostic criteria of HZ/VZV meningitis (<xref rid="B16" ref-type="bibr">16</xref>); 3). Within 2 weeks of onset; 4). Diagnosed with shingles for the first time and had not used anticoagulants in the last 2 weeks. The diagnosis of shingles is made by a dermatologist and the diagnosis of VZV meningitis is made by a neurologist.</p><p>Exclusion criteria: 1). zoster sine herpete; 2). lactating or pregnant women; 3). infections caused by pathogens other than VZV.</p></sec><sec id="s2_2"><title>Methods</title><sec id="s2_2_1"><title>Data collection</title><p>We collected the general information of the patients, including ages, genders, clinical characteristics (mainly including the courses of diseases, the sites of herpes, treatments, etc.), comorbidity, and previous medical records.</p></sec><sec id="s2_2_2"><title>Test of plasma coagulation function</title><p>Five mL of venous blood was collected from each enrolled patient and control subject on the morning of the second day of admission by anticoagulant vessels (containing 0.2ml, 0.11mol/L sodium citrate anticoagulant) under aseptic conditions, thoroughly mixed, left at normal temperature (processed within 4 hours). Plasma was collected by centrifugation at 3000r/min for 15 minutes. Levels of fibrinogen (Fib) and D-dimer (DD), prothrombin time PT), active partial thromboplastin time (APTT), thrombin time (TT) were measured on the automatic coagulation analyzer CS-5100 (Sysmex Corporation, Japan) in accordance with the operating procedures.</p></sec><sec id="s2_2_3"><title>Routine and biochemical tests of cerebrospinal fluid</title><p>According to the clinical manifestations, lumbar puncture was performed within 48 hours after admission for patients with suspected VZV-related CNS infection with the consent of the patients or their families, and 6 mL cerebrospinal fluid was obtained with sterile test tubes. White blood cell count, glucose, protein, chlorine, adenosine deaminase (ADA), lactate dehydrogenase (LDH) and VZV DNA concentrations were determined.</p></sec><sec id="s2_2_4"><title>Cerebrospinal fluid proteomics</title><p>CSF level of 8 coagulation proteins (Fibrinogen, Antithrombin-III, Coagulation factor VII, IX, X, XI, XII, XIIIa) were extracted from previously collected CSF proteomics dataset of the same 28 VZV meningitis and 11 herpes zoster (HZ) patients (<xref rid="B17" ref-type="bibr">17</xref>). Briefly, the proteins from CSF samples analyzed by mass spectrometry using data-independent acquisition (DIA) method for quantitation. Relative protein intensity in each sample was log2 transformed prior to statistical analysis.</p></sec><sec id="s2_2_5"><title>Statistical analysis</title><p>SPSS 20.0 software (Chicago, IL, USA) was used for data processing and statistical analysis. Normal distribution data of measurement data were expressed as mean &#x000b1; standard deviation (x &#x000b1; SD), and non-normal distribution data were expressed as M (Q1 ~ Q3). One-way analysis of variance (ANOVA) was used to compare the mean of multiple groups; S-N-K method was used to test the comparison between two groups; counting data were expressed by frequency and percentage; Chi-square test or Fisher exact test was used for comparison between groups. Univariate and multivariate logistic regression analysis were performed to identify independent risk factors, and Pearson analysis was used for correlation analysis. P&#x0003c; 0.05 (two-tailed) was considered statistically significant.</p></sec></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Baseline characteristics of patients</title><p>According to the inclusion/exclusion criteria, 95 HZ patients were included: 45 males and 50 females, with ages 23 to 88 years (59.6 &#x000b1; 14.5 years). There were 28 patients with VZVM: 21 males and 7 females, with ages from 24 to 88 years (56.5 &#x000b1; 16.3). The HCs group consisted of 47 cases: 26 males and 21 females, with ages from 24 to 88 years (62.2 &#x000b1; 16.1 years). There was no significant difference (P&#x0003e;0.05) in age and comorbidity (hypertension, diabetes, stroke, coronary heart disease, tumor, chronic obstructive pulmonary disease, immune diseases, immune drug use, etc.) among the three groups except gender (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of patients in different groups on admission.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="middle" align="left" rowspan="1" colspan="1">VZVM group (n=28)</th><th valign="middle" align="left" rowspan="1" colspan="1">HZ group (n=95)</th><th valign="middle" align="left" rowspan="1" colspan="1">HCs group (n=47)</th><th valign="middle" align="left" rowspan="1" colspan="1">F/x<sup>2</sup>
</th><th valign="middle" align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age (mean &#x000b1; SD) (years)</td><td valign="middle" align="left" rowspan="1" colspan="1">56.5 &#x000b1; 16.3</td><td valign="middle" align="left" rowspan="1" colspan="1">59.6 &#x000b1; 14.5</td><td valign="middle" align="left" rowspan="1" colspan="1">62.2 &#x000b1; 16.1</td><td valign="middle" align="right" rowspan="1" colspan="1">1.256</td><td valign="middle" align="right" rowspan="1" colspan="1">0.2875</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Gender</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Male (numbers,%)</td><td valign="middle" align="left" rowspan="1" colspan="1">21 (75.0%)**</td><td valign="middle" align="left" rowspan="1" colspan="1">45 (47.4%) 50 (52.6%)</td><td valign="middle" align="left" rowspan="1" colspan="1">26 (55.3%)</td><td valign="middle" align="right" rowspan="1" colspan="1">6.6875</td><td valign="middle" align="right" rowspan="1" colspan="1">0.0353</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Female (numbers,%)</td><td valign="middle" align="left" rowspan="1" colspan="1">7 (25.0%)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;</td><td valign="middle" align="left" rowspan="1" colspan="1">21 (44.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Course of disease (days)</td><td valign="middle" align="left" rowspan="1" colspan="1">6.1 &#x000b1; 4.4</td><td valign="middle" align="left" rowspan="1" colspan="1">5.5 &#x000b1; 3.5</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">0.6693</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5046</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Comorbidity (cases)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Coronary heart disease</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="middle" align="right" rowspan="1" colspan="1">1.396</td><td valign="middle" align="right" rowspan="1" colspan="1">0.4976</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;COPD</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">1.2266</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5416</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td valign="middle" align="right" rowspan="1" colspan="1">10</td><td valign="middle" align="right" rowspan="1" colspan="1">35</td><td valign="middle" align="right" rowspan="1" colspan="1">23</td><td valign="middle" align="right" rowspan="1" colspan="1">2.1729</td><td valign="middle" align="right" rowspan="1" colspan="1">0.3374</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Immune diseases</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="middle" align="right" rowspan="1" colspan="1">0.4271</td><td valign="middle" align="right" rowspan="1" colspan="1">0.8077</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Use of immune drugs</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">1.1484</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5631</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Stroke</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">5</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="middle" align="right" rowspan="1" colspan="1">3.1688</td><td valign="middle" align="right" rowspan="1" colspan="1">0.2051</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Diabetes</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="middle" align="right" rowspan="1" colspan="1">13</td><td valign="middle" align="right" rowspan="1" colspan="1">9</td><td valign="middle" align="right" rowspan="1" colspan="1">1.1744</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5559</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Chronic kidney disease</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">3.5812</td><td valign="middle" align="right" rowspan="1" colspan="1">0.1669</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Chronic liver disease</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">0.2167</td><td valign="middle" align="right" rowspan="1" colspan="1">0.8973</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Tumor</td><td valign="middle" align="right" rowspan="1" colspan="1">0</td><td valign="middle" align="right" rowspan="1" colspan="1">6</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">2.8365</td><td valign="middle" align="right" rowspan="1" colspan="1">0.2421</td></tr><tr><th valign="middle" colspan="6" align="left" rowspan="1">Herpes zoster site (numbers)</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Head and face</td><td valign="middle" align="right" rowspan="1" colspan="1">20</td><td valign="middle" align="right" rowspan="1" colspan="1">59</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">0.8182</td><td valign="middle" align="right" rowspan="1" colspan="1">0.3657</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Neck</td><td valign="middle" align="right" rowspan="1" colspan="1">3</td><td valign="middle" align="right" rowspan="1" colspan="1">5</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">1.0567</td><td valign="middle" align="right" rowspan="1" colspan="1">0.304</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Chest and back</td><td valign="middle" align="right" rowspan="1" colspan="1">4</td><td valign="middle" align="right" rowspan="1" colspan="1">18</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">0.32</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5716</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Waist</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">12</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">1.8781</td><td valign="middle" align="right" rowspan="1" colspan="1">0.1705</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Limb</td><td valign="middle" align="right" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">7</td><td valign="middle" align="left" rowspan="1" colspan="1">NA</td><td valign="middle" align="right" rowspan="1" colspan="1">0.5127</td><td valign="middle" align="right" rowspan="1" colspan="1">0.474</td></tr></tbody></table><table-wrap-foot><fn><p>**P&#x0003c;0.01 <italic>vs</italic> HZ group; NA, not applicable; COPD, chronic obstructive pulmonary disease.</p></fn></table-wrap-foot></table-wrap><p>In the HZ group, shingle were found in 59 cases located on the head and face, 5 on the neck, 18 on the chest and back, 12 on the waist and 7 on the limbs. Among the 28 VZVM patients, 20 on the head and face, 3 on the neck, 4 on the chest and back, 1 on the waist and 1 on the limbs. There was no difference in shingle sites between the two groups (P&#x0003e;0.05). The proportion of males in VZVM group was significantly higher than the HZ group (P&#x0003c;0.01).</p></sec><sec id="s3_2"><title>Comparison of coagulation parameters among three groups</title><p>There were significantly increased levels of circulating Fib and DD in HZ and VZVM patients compared to the HCs (F=4.627, P&#x0003c;0.01; F=5.791, P&#x0003c;0.01), but there were no significant differences in PT, APTT, INR and TT levels among the three groups (P&#x0003e;0.05), as shown in <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>, <xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>. Inter-group comparison showed that there was no significant difference in coagulation parameters between the HZ group and the VZVM group (P&#x0003e;0.05).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Comparison of plasma Fib <bold>(A)</bold> and DD <bold>(B)</bold> levels among three groups. HCs, health controls; HZ, herpes zoster; VZVM, varicella-zoster virus meningitis. ** P&#x0003c;0.01.</p></caption><graphic xlink:href="fimmu-16-1511901-g001" position="float"/></fig><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Comparison of coagulation parameters among three groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">VZVM (n=28)</th><th valign="top" align="left" rowspan="1" colspan="1">HZ (n=95)</th><th valign="top" align="left" rowspan="1" colspan="1">HCs (n=47)</th><th valign="top" align="left" rowspan="1" colspan="1">F</th><th valign="top" align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">PT(sec)</td><td valign="top" align="left" rowspan="1" colspan="1">11.2 &#x000b1; 0.7</td><td valign="top" align="left" rowspan="1" colspan="1">11.3 &#x000b1; 0.7</td><td valign="top" align="left" rowspan="1" colspan="1">11.4 &#x000b1; 0.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.7124</td><td valign="top" align="left" rowspan="1" colspan="1">0.4920</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">INR</td><td valign="top" align="left" rowspan="1" colspan="1">1.0 &#x000b1; 0.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.0 &#x000b1; 0.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.0 &#x000b1; 0.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.6024</td><td valign="top" align="left" rowspan="1" colspan="1">0.5487</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fib(g/L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 &#x000b1; 0.7**</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 &#x000b1; 0.9**</td><td valign="top" align="left" rowspan="1" colspan="1">2.8 &#x000b1; 0.5</td><td valign="top" align="left" rowspan="1" colspan="1">4.6270</td><td valign="top" align="left" rowspan="1" colspan="1">0.0111</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TT (sec)</td><td valign="top" align="left" rowspan="1" colspan="1">19.0 &#x000b1; 1.0</td><td valign="top" align="left" rowspan="1" colspan="1">18.9 &#x000b1; 1.2</td><td valign="top" align="left" rowspan="1" colspan="1">18.7 &#x000b1; 1.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.4263</td><td valign="top" align="left" rowspan="1" colspan="1">0.6536</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APTT (sec)</td><td valign="top" align="left" rowspan="1" colspan="1">27.0 &#x000b1; 1.7</td><td valign="top" align="left" rowspan="1" colspan="1">26.7 &#x000b1; 2.4</td><td valign="top" align="left" rowspan="1" colspan="1">26.6 &#x000b1; 2.0</td><td valign="top" align="left" rowspan="1" colspan="1">6.3924</td><td valign="top" align="left" rowspan="1" colspan="1">0.6761</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DD (mg/L)</td><td valign="top" align="left" rowspan="1" colspan="1">0.4 (0.2,0.5)**</td><td valign="top" align="left" rowspan="1" colspan="1">0.4 (0.2,0.7)**</td><td valign="top" align="left" rowspan="1" colspan="1">0.2 (0.1,0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5.7910</td><td valign="top" align="left" rowspan="1" colspan="1">0.0037</td></tr></tbody></table><table-wrap-foot><fn><p>**P&#x0003c;0.01 <italic>vs</italic> HCs group. PT, prothrombin time; INR, international normalized ratio; Fib, fibrinogen; TT, thrombin time; APTT, active partial thromboplastin time; DD, D-dimer.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_3"><title>Multivariate logistic regression analysis</title><p>Multivariate logistic regression analysis was performed with the occurrence of meningitis as the dependent variable, and the factors with P&#x0003c;0.5 in univariate analysis (age, course of disease, gender, Fib, DD) as the independent variables (<xref rid="T3" ref-type="table">
<bold>Table&#x000a0;3</bold>
</xref>). Male was the independent risk factor for VZV meningitis in HZ patients. However, coagulation function parameters and other factors were not independent risk factors (P&#x0003e;0.05).</p><table-wrap position="float" id="T3"><label>Table&#x000a0;3</label><caption><p>Multivariate logistic regression analysis of meningitis in HZ patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">&#x003b2; value</th><th valign="top" align="left" rowspan="1" colspan="1">SE value</th><th valign="top" align="left" rowspan="1" colspan="1">Wald</th><th valign="top" align="left" rowspan="1" colspan="1">OR value</th><th valign="top" align="left" rowspan="1" colspan="1">95%CI</th><th valign="top" align="left" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age</td><td valign="top" align="left" rowspan="1" colspan="1">-0.008</td><td valign="top" align="left" rowspan="1" colspan="1">0.015</td><td valign="top" align="left" rowspan="1" colspan="1">0.298</td><td valign="top" align="left" rowspan="1" colspan="1">0.992</td><td valign="top" align="left" rowspan="1" colspan="1">0.962-1.022</td><td valign="top" align="left" rowspan="1" colspan="1">0.585</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Course of disease</td><td valign="top" align="left" rowspan="1" colspan="1">0.067</td><td valign="top" align="left" rowspan="1" colspan="1">0.056</td><td valign="top" align="left" rowspan="1" colspan="1">1.425</td><td valign="top" align="left" rowspan="1" colspan="1">1.070</td><td valign="top" align="left" rowspan="1" colspan="1">0.958-1.194</td><td valign="top" align="left" rowspan="1" colspan="1">0.233</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1">-1.359</td><td valign="top" align="left" rowspan="1" colspan="1">0.526</td><td valign="top" align="left" rowspan="1" colspan="1">6.684</td><td valign="top" align="left" rowspan="1" colspan="1">0.257</td><td valign="top" align="left" rowspan="1" colspan="1">0.092-0.720</td><td valign="top" align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fib</td><td valign="top" align="left" rowspan="1" colspan="1">-0.056</td><td valign="top" align="left" rowspan="1" colspan="1">0.107</td><td valign="top" align="left" rowspan="1" colspan="1">0.277</td><td valign="top" align="left" rowspan="1" colspan="1">0.945</td><td valign="top" align="left" rowspan="1" colspan="1">0.767-1.166</td><td valign="top" align="left" rowspan="1" colspan="1">0.598</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DD</td><td valign="top" align="left" rowspan="1" colspan="1">-0.359</td><td valign="top" align="left" rowspan="1" colspan="1">0.427</td><td valign="top" align="left" rowspan="1" colspan="1">0.706</td><td valign="top" align="left" rowspan="1" colspan="1">0.698</td><td valign="top" align="left" rowspan="1" colspan="1">0.302-1.614</td><td valign="top" align="left" rowspan="1" colspan="1">0.401</td></tr></tbody></table><table-wrap-foot><fn><p>Fib, fibrinogen; DD, D-dimer.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_4"><title>Correlation analysis of plasma coagulation function and CSF parameters in VZVM patients</title><p>All 28 VZVM patients and 11 of the 95 HZ patients completed lumbar puncture and CSF examination. In patients with VZVM group, the white blood cell counts and protein content in CSF were all higher than the normal range, but the levels of glucose, chlorine, ADA and LDH in CSF were in the normal range. There was no significant correlation between blood coagulation parameters and the levels of white blood cell counts, protein and glucose in CSF (P&#x0003e;0.05).</p></sec><sec id="s3_5"><title>Comparison of coagulation factors in CSF proteomes in 28 VZVM patients and 11 HZ patients</title><p>Previously reported CSF proteomics data for 28 VZVM and 11 HZ patients (<xref rid="B17" ref-type="bibr">17</xref>) was reinterpreted to focus on coagulation markers. Compared with HZ patients, there were no differences in the expression levels of Fib, AT-III and coagulation factor VII, IX, X, XI in VZVM patients (P&#x0003e;0.05, <xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>), but the expression levels of coagulation factor XII and XIIIa in VZVM patients were significantly higher than those in HZ patients (P&#x0003c;0.05, P&#x0003c;0.01, <xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>The expression levels of Fib <bold>(A)</bold>, antithrombin III <bold>(B)</bold> and coagulation factor VII <bold>(C)</bold>, IX <bold>(D)</bold>, X <bold>(E)</bold>, XI <bold>(F)</bold> in CSF between HZ and VZVM groups.</p></caption><graphic xlink:href="fimmu-16-1511901-g002" position="float"/></fig><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>The expression levels of coagulation factors XII <bold>(A)</bold> and XIIIa <bold>(B)</bold> in VZVM group and HZ group.</p></caption><graphic xlink:href="fimmu-16-1511901-g003" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Herpes zoster is caused by reactivated VZV, mostly in middle-aged and elderly people. With global rising of HZ incidence, 20% to 30% of people suffer from HZ in their lifetime (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), and 50% of people with HZ will have a concomitant VZV viremia (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Moreover, the patients may develop various complications upon onset, including lethal CNS complications. In the case of HZ, early and timely treatment can significantly reduce the incidence of complications. Older age, diabetes mellitus, immunosuppression, and treatment delay might serve as risk factors for CNS infection in HZ patients (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Kim et&#x000a0;al. (<xref rid="B21" ref-type="bibr">21</xref>) found that the incidence of VZV-related meningitis in male was significantly higher than that of female. In agreement, male gender was independently associated with an increased risk of meningitis in our study.</p><p>Viral invasion can trigger homeostatic disorders within the host, including changes in coagulation function, and even lead to severe complications such as pulmonary embolism and life-threatening DIC (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>). The parameters of coagulation function include APTT, PT, TT, Fib and DD, etc. Monitoring coagulation biomarkers which correlate with disease severity can inform therapeutic strategies. Limb et&#x000a0;al. (<xref rid="B22" ref-type="bibr">22</xref>) first reported a case of amputation in an adult male with shingles complicated by pneumonia and peripheral venous thrombosis in 2009. Since then, deep vein thrombosis has been confirmed repeatedly in HZ patients (<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>), while pulmonary embolism can also be complicated in shingles patients (<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>), and the risk of stroke is significantly increased (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). These results indicate that VZV infection can also lead to changes in blood coagulation function in patients. In this study, we found plasma Fib and DD levels were significantly increased in patients with HZ and meningitis as compared to HCs. As a liver-derived coagulation protein, fibrinogen (Fib) primary substrate for both hemostasis and thrombosis, and serves as a principal determinant of coagulation capacity (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). In addition, Fib also binds to platelet membrane glycoprotein IIb/IIIa to mediate platelet aggregation, thus affecting&#x000a0;blood viscosity. Increasing Fib level will lead to increased fibrin leveland therefore creats a hypercoagulable state (<xref rid="B33" ref-type="bibr">33</xref>). DD is one of the degradation products of fibrin and fibrinogen after activation of coagulation-fibrinolytic system, and is a marker reflecting fibrinolytic activity <italic>in vivo</italic>. The increase of plasma DD often occurs in patients with venous thrombosis, infection, hypercoagulable state, etc. (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). This study reveals that acute herpes zoster infection is characterized by enhanced coagulation functions, compensatory fibrinolysis activation, and consequent disruption of hemostatic balance, resulting in a prothrombotic state. However, our study found that although the plasma Fib and DD levels in patients with VZV meningitis were higher than those in the control group, there was no significant difference in all coagulation function parameters compared with HZ patients. Further analysis showed that abnormal coagulation function was not an independent risk factor for meningitis in patients with shingles. Therefore, we speculate that hypercoagulability is not the pathophysiological mechanism of VZV meningitis, which needed to be validated in further studies.</p><p>CSF composition changes resulting from microbial or macromolecular infiltration correlate with CNS microenvironment alterations, serving as potential lesion biomarkers. Proteomics provides comprehensive protein quantification in biological systems, aiding pathophysiological understanding. Proteomic analyses of brain or CSF in normal and diseased states, helps to identify disease-associated proteins with diagnostic, therapeutic and prognostic relevance (<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B38" ref-type="bibr">38</xref>). Our previous study (<xref rid="B17" ref-type="bibr">17</xref>) on CSF proteomics in patients with VZV meningitis also found that the expression of CXCL10, IL-1RN, MPO, PRTN3 and other proteins which reflecting inflammation and immune cell activation were significantly increased. Ramachandran et&#x000a0;al. have also found inflammatory markers elevated in the CSF during VZV-related meningitis, including interferon gamma, interleukins IL-6, IL-8, IL-10, IL-17F, IL-1RA, chemokines CXCL-9, CXCL-10, CCL-2 and G-CSF (<xref rid="B39" ref-type="bibr">39</xref>). Such inflammatory response is closely related to the coagulation system, and there is mutual regulation between the two systems (<xref rid="B40" ref-type="bibr">40</xref>). The inflammatory response of the brain can lead to increased clotting function, and anticoagulation can reduce the damage of the inflammatory response (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). It is likely that the observed upregulation of coagulation factors XII and XIIIa in the CSF of VZV meningitis patients is more consistent with an inflammatory response causing BBB permeability rather than with intrinsic coagulation pathway activation. Therefore, based on the results of this study, we speculate that hypercoagulable state is not involved in the pathogenesis of VZV meningitis. The pathogenesis of VZV meningitis may be different from that of VZV encephalitis, and further comparative studies are needed to clarify it in the future. A retrospective study by Kim et&#x000a0;al. to identify risk factors for CNS infection in 578 acute HZ patients, including 24 cases of HZ-related meningitis, in addition to discovering that males are a risk factor for VZVM, they also found that meningitis were more common in patients who had shingles in the craniocervical dermatomes, skin lesions on craniocervical distribution is also a risk factor for subsequent meningitis, and they pointed out that hematogenous invasion of virus may play a role in CNS VZV infections (<xref rid="B21" ref-type="bibr">21</xref>). According to studies by Satyaprakash and Kennedy et&#x000a0;al. (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>), approximately 50% of herpes zoster patients have viremia, which is an important pathophysiological mechanism for the concurrent CNS infection in HZ patients. Is the inflammatory response in VZVM patients caused by viremia? It is possible that the more severe cases of HZ with meningitis are among those 50% of HZ patients who have a viremia. In future studies, we will consider testing for viremia by measuring VZV DNA in the blood of HZ and VZVM patients by PCR technology.</p><p>A limitation of this study is the relatively small cohort of VZV meningitis patients, particularly the limited number of HZ cases who underwent diagnostic lumbar puncture for CSF analysis, which may have introduced bias in our findings. Moreover, the absence of longitudinal data tracking individual patients&#x02019; pre- and post-treatment progression limits our ability to establish prognostic indicators for clinical outcomes. In the future, larger scale and multi-center studies are needed to further explore the effects of coagulation screening indicators on clinical outcomes and the need for preventive antithrombotic therapy.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>Reactivation of VZV can lead to changes in coagulation function in the host. Both HZ and VZV meningitis patients have hypercoagulable internal environment, mainly characterized by elevated fibrinogen and D-dimer, but such environment does not seem to be a risk factor for CNS infection. Disruption of the BBB in patients with VZV meningitis may lead to changes in partial coagulation parameters, but the pathogenesis of CNS infection in HZ may not be related to hypercoagulability. Further large-scale, multi-center, controlled studies are needed to clarify it in the future, and simultaneously detect viremia to verify our hypothesis.</p></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by Hangzhou Third People&#x02019;s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>YRY: Conceptualization, Data curation, Investigation, Project administration, Writing &#x02013; original draft. JG: Data curation, Formal Analysis, Investigation, Writing &#x02013; original draft. HL: Data curation, Formal Analysis, Investigation, Writing &#x02013; review &#x00026; editing. YW: Formal Analysis, Methodology, Software, Writing &#x02013; review &#x00026; editing. ZS: Formal Analysis, Funding acquisition, Supervision, Writing &#x02013; review &#x00026; editing. DP: Formal Analysis, Funding acquisition, Investigation, Writing &#x02013; review &#x00026; editing. YXY: Conceptualization, Formal Analysis, Funding acquisition, Project administration, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrei</surname><given-names>G</given-names></name><name><surname>Snoeck</surname><given-names>R</given-names></name></person-group>. <article-title>Advances and perspectives in the management of varicella-zoster virus infections</article-title>. <source>Molecules (Basel Switzerland)</source>. (<year>2021</year>) <volume>26</volume>:<elocation-id>1132</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/molecules26041132</pub-id>
<pub-id pub-id-type="pmid">33672709</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>PGE</given-names></name></person-group>. <article-title>The spectrum of neurological manifestations of varicella-zoster virus reactivation</article-title>. <source>Viruses</source>. (<year>2023</year>) <volume>15</volume>:<elocation-id>1663</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/v15081663</pub-id>
<pub-id pub-id-type="pmid">37632006</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hass</surname><given-names>RM</given-names></name><name><surname>Sturgill</surname><given-names>FL</given-names></name><name><surname>Young</surname><given-names>NP</given-names></name></person-group>. <article-title>Sensory and motor neurologic presentations of herpes zoster (Shingles)</article-title>. <source>Mayo Clin Proc</source>. (<year>2023</year>) <volume>98</volume>:<page-range>1128&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.mayocp.2023.03.009</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bricout</surname><given-names>H</given-names></name><name><surname>Haugh</surname><given-names>M</given-names></name><name><surname>Olatunde</surname><given-names>O</given-names></name><name><surname>Prieto</surname><given-names>RG</given-names></name></person-group>. <article-title>Herpes zoster-associated mortality in Europe: a systematic review</article-title>. <source>BMC Public Health</source>. (<year>2015</year>) <volume>15</volume>:<fpage>466</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12889-015-1753-y</pub-id>
<pub-id pub-id-type="pmid">25940080</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saguil</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>S</given-names></name><name><surname>Mercado</surname><given-names>M</given-names></name><name><surname>Lauters</surname><given-names>R</given-names></name></person-group>. <article-title>Herpes zoster and postherpetic neuralgia: prevention and management</article-title>. <source>Am Fam Physician</source>. (<year>2017</year>) <volume>96</volume>:<page-range>656&#x02013;63</page-range>.</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maher</surname><given-names>MD</given-names></name><name><surname>Douglas</surname><given-names>VP</given-names></name><name><surname>Douglas</surname><given-names>KAA</given-names></name><name><surname>Collens</surname><given-names>SI</given-names></name><name><surname>Gilbert</surname><given-names>AL</given-names></name><name><surname>Torun</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Clinical and neuroradiologic characteristics in varicella zoster virus reactivation with central nervous system involvement</article-title>. <source>J Neurol Sci</source>. (<year>2022</year>) <volume>437</volume>:<elocation-id>120262</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jns.2022.120262</pub-id>
<pub-id pub-id-type="pmid">35489173</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Satyaprakash</surname><given-names>AK</given-names></name><name><surname>Tremaine</surname><given-names>AM</given-names></name><name><surname>Stelter</surname><given-names>AA</given-names></name><name><surname>Creed</surname><given-names>R</given-names></name><name><surname>Ravanfar</surname><given-names>P</given-names></name><name><surname>Mendoza</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Viremia in acute herpes zoster</article-title>. <source>J Infect Dis</source>. (<year>2009</year>) <volume>200</volume>:<fpage>26</fpage>&#x02013;<lpage>32</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1086/599381</pub-id>
<pub-id pub-id-type="pmid">19469706</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>PGE</given-names></name><name><surname>Grose</surname><given-names>C</given-names></name></person-group>. <article-title>Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination</article-title>. <source>J Virol</source>. (<year>2025</year>) <volume>99</volume>:<elocation-id>e0181624</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/jvi.01816-24</pub-id>
<pub-id pub-id-type="pmid">39818965</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levin</surname><given-names>MJ</given-names></name><name><surname>Cai</surname><given-names>GY</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Rouphael</surname><given-names>NG</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Canniff</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Varicella-zoster virus DNA in blood after administration of herpes zoster vaccine</article-title>. <source>J Infect Dis</source>. (<year>2018</year>) <volume>217</volume>:<page-range>1055&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/infdis/jix653</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>Meningitis/meningoencephalitis caused by varicella zoster virus reactivation: a retrospective single-center case series study</article-title>. <source>Am J Transl Res</source>. (<year>2022</year>) <volume>14</volume>:<fpage>491</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">35173869</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hung</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>KH</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Liao</surname><given-names>MF</given-names></name><name><surname>Tsai</surname><given-names>YT</given-names></name><etal/></person-group>. <article-title>Features of varicella zoster virus myelitis and dependence on immune status</article-title>. <source>J Neurol Sci</source>. (<year>2012</year>) <volume>318</volume>:<fpage>19</fpage>&#x02013;<lpage>24</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jns.2012.04.017</pub-id>
<pub-id pub-id-type="pmid">22564884</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagel</surname><given-names>MA</given-names></name><name><surname>Niemeyer</surname><given-names>CS</given-names></name><name><surname>Bubak</surname><given-names>AN</given-names></name></person-group>. <article-title>Central nervous system infections produced by varicella zoster virus</article-title>. <source>Curr Opin Infect Dis</source>. (<year>2020</year>) <volume>33</volume>:<page-range>273&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/QCO.0000000000000647</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Scharrer</surname><given-names>I</given-names></name></person-group>. <article-title>Procoagulant activity during viral infections</article-title>. <source>Front Biosci (Landmark edition)</source>. (<year>2018</year>) <volume>23</volume>:<page-range>1060&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2741/4633</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group>. <article-title>Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia</article-title>. <source>Cell Mol Immunol</source>. (<year>2016</year>) <volume>13</volume>:<page-range>432&#x02013;42</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cmi.2016.1</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asakura</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name></person-group>. <article-title>COVID-19-associated coagulopathy and disseminated intravascular coagulation</article-title>. <source>Int J Hematol</source>. (<year>2021</year>) <volume>113</volume>:<fpage>45</fpage>&#x02013;<lpage>57</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12185-020-03029-y</pub-id>
<pub-id pub-id-type="pmid">33161508</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Werner</surname><given-names>RN</given-names></name><name><surname>Nikkels</surname><given-names>AF</given-names></name><name><surname>Marinovi&#x00107;</surname><given-names>B</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>M</given-names></name><name><surname>Czarnecka-Operacz</surname><given-names>M</given-names></name><name><surname>Agius</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>European consensus-based (S2k) guideline on the management of herpes zoster-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis</article-title>. <source>JEADV</source>. (<year>2017</year>) <volume>31</volume>:<fpage>9</fpage>&#x02013;<lpage>19</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/jdv.13995</pub-id>
<pub-id pub-id-type="pmid">27804172</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Cerebrospinal fluid proteomics in meningitis patients with reactivated varicella zoster virus</article-title>. <source>Immun Inflammation Dis</source>. (<year>2023</year>) <volume>11</volume>:<elocation-id>e1038</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/iid3.1038</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Suo</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group>. <article-title>The incidence of herpes zoster in China: A meta-analysis and evidence quality assessment</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2023</year>) <volume>19</volume>:<elocation-id>2228169</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/21645515.2023.2228169</pub-id>
<pub-id pub-id-type="pmid">37424092</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosamilia</surname><given-names>LL</given-names></name></person-group>. <article-title>Herpes zoster presentation, management, and prevention: A modern case-based review</article-title>. <source>Am J Clin Dermatol</source>. (<year>2020</year>) <volume>21</volume>:<fpage>97</fpage>&#x02013;<lpage>107</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s40257-019-00483-1</pub-id>
<pub-id pub-id-type="pmid">31741185</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carey</surname><given-names>RAB</given-names></name><name><surname>Chandiraseharan</surname><given-names>VK</given-names></name><name><surname>Jasper</surname><given-names>A</given-names></name><name><surname>Sebastian</surname><given-names>T</given-names></name><name><surname>Gujjarlamudi</surname><given-names>C</given-names></name><name><surname>Sathyendra</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Varicella zoster virus infection of the central nervous system - 10 year experience from a tertiary hospital in south India</article-title>. <source>Ann Indian Acad Neurol</source>. (<year>2017</year>) <volume>20</volume>:<page-range>149&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4103/aian.AIAN_484_16</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Choi</surname><given-names>KH</given-names></name><name><surname>Nam</surname><given-names>TS</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Risk factors for aseptic meningitis in herpes zoster patients</article-title>. <source>Ann Dermatol</source>. (<year>2017</year>) <volume>29</volume>:<page-range>283&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.5021/ad.2017.29.3.283</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Limb</surname><given-names>J</given-names></name><name><surname>Binning</surname><given-names>A</given-names></name></person-group>. <article-title>Thrombosis associated with varicella zoster in an adult</article-title>. <source>Int J Infect Dis</source>. (<year>2009</year>) <volume>13</volume>:<page-range>e498&#x02013;500</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijid.2009.02.007</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maity</surname><given-names>PK</given-names></name><name><surname>Chakrabarti</surname><given-names>N</given-names></name><name><surname>Mondal</surname><given-names>M</given-names></name><name><surname>Patar</surname><given-names>K</given-names></name><name><surname>Mukhopadhyay</surname><given-names>M</given-names></name></person-group>. <article-title>Deep vein thrombosis: A rare signature of herpes zoster</article-title>. <source>J Assoc Physicians India</source>. (<year>2014</year>) <volume>62</volume>:<page-range>72&#x02013;4</page-range>.</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>T</given-names></name></person-group>. <article-title>Nagpal K.Herpes zoster meningoencephalitis complicated with peripheral vascular disease: an uncommon presentation of a common disease</article-title>. <source>Scand J Infect Dis</source>. (<year>2014</year>) <volume>46</volume>:<page-range>716&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3109/00365548.2014.926022</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dogan</surname><given-names>M</given-names></name><name><surname>Acikgoz</surname><given-names>M</given-names></name><name><surname>Bora</surname><given-names>A</given-names></name><name><surname>Ba&#x0015f;arano&#x0011f;lu</surname><given-names>M</given-names></name><name><surname>Oner</surname><given-names>AF</given-names></name></person-group>. <article-title>Varicella-associated purpura fulminans and multiple deep vein thromboses: a case report</article-title>. <source>J Nippon Med Sch</source>. (<year>2009</year>) <volume>76</volume>:<page-range>165&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1272/jnms.76.165</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salvotti</surname><given-names>F</given-names></name><name><surname>Trapletti</surname><given-names>S</given-names></name><name><surname>Chiarini</surname><given-names>G</given-names></name><name><surname>Castellano</surname><given-names>M</given-names></name><name><surname>Muiesan</surname><given-names>ML</given-names></name></person-group>. <article-title>Atypical varicella-Zoster virus reactivation: A case report</article-title>. <source>Eur J Case Rep Intern Med</source>. (<year>2023</year>) <volume>10</volume>:<elocation-id>3945</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.12890/2023_003945</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Yasmeen</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>AK</given-names></name><name><surname>Saffar</surname><given-names>KA</given-names></name><name><surname>Narayanan</surname><given-names>SR</given-names></name></person-group>. <article-title>Cerebral venous thrombosis and acute pulmonary embolism following varicella infection</article-title>. <source>Eur J Case Rep Intern Med</source>. (<year>2019</year>) <volume>6</volume>:<elocation-id>1171</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.12890/2019_001171</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sahra</surname><given-names>S</given-names></name><name><surname>Jahangir</surname><given-names>A</given-names></name><name><surname>Gavica</surname><given-names>MC</given-names></name><name><surname>Mobarakai</surname><given-names>N</given-names></name><name><surname>Jahangir</surname><given-names>A</given-names></name></person-group>. <article-title>First case report of pulmonary embolism with Zoster Sine Herpete</article-title>. <source>Respir Med Case Rep</source>. (<year>2021</year>) <volume>33</volume>:<elocation-id>101462</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.rmcr.2021.101462</pub-id>
<pub-id pub-id-type="pmid">34401298</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horev</surname><given-names>A</given-names></name><name><surname>Horev</surname><given-names>A</given-names></name><name><surname>Gordon-Irshai</surname><given-names>A</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Andre</surname><given-names>N</given-names></name><name><surname>Ifergane</surname><given-names>G</given-names></name></person-group>. <article-title>Herpes zoster and long-term vascular risk: a retrospective cohort study</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>2364</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-023-29667-w</pub-id>
<pub-id pub-id-type="pmid">36759695</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group>. <article-title>Stroke risk after varicella-zoster virus infection: a systematic review and meta-analysis</article-title>. <source>J Neurovirol</source>. (<year>2023</year>) <volume>29</volume>:<page-range>449&#x02013;59</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13365-023-01144-0</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weisel</surname><given-names>JW</given-names></name><name><surname>Litvinov</surname><given-names>RI</given-names></name></person-group>. <article-title>Fibrin formation, structure and properties</article-title>. <source>Subcell Biochem</source>. (<year>2017</year>) <volume>82</volume>:<page-range>405&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/978-3-319-49674-0_13</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wolberg</surname><given-names>AS</given-names></name></person-group>. <article-title>Fibrinogen and fibrin: synthesis, structure, and function in health and disease</article-title>. <source>J Thromb Haemost</source>. (<year>2023</year>) <volume>21</volume>:<page-range>3005&#x02013;15</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jtha.2023.08.014</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nurden</surname><given-names>AT</given-names></name></person-group>. <article-title>Association of fibrinogen-bound glycoprotein IIb-IIIa complexes on the activated platelet surface</article-title>. <source>J Lab Clin Med</source>. (<year>1996</year>) <volume>128</volume>:<fpage>7</fpage>&#x02013;<lpage>8</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0022-2143(96)90107-9</pub-id>
<pub-id pub-id-type="pmid">8759930</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pl&#x000fc;ddemann</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>CP</given-names></name><name><surname>Wolstenholme</surname><given-names>J</given-names></name><name><surname>Heneghan</surname><given-names>C</given-names></name></person-group>. <article-title>The D-Dimer test in combination with a decision rule for ruling out deep vein thrombosis in primary care: diagnostic technology update</article-title>. <source>Br J Gen Pract</source>. (<year>2012</year>) <volume>62</volume>:<page-range>e393&#x02013;395</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3399/bjgp12X641645</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schouten</surname><given-names>HJ</given-names></name><name><surname>Geersing</surname><given-names>GJ</given-names></name><name><surname>Koek</surname><given-names>HL</given-names></name><name><surname>Zuithoff</surname><given-names>NP</given-names></name><name><surname>Janssen</surname><given-names>KJ</given-names></name><name><surname>Douma</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and Meta-analysis</article-title>. <source>BMJ</source>. (<year>2013</year>) <volume>346</volume>:<elocation-id>f2492</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bmj.f2492</pub-id>
<pub-id pub-id-type="pmid">23645857</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bader</surname><given-names>JM</given-names></name><name><surname>Geyer</surname><given-names>PE</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>JB</given-names></name><name><surname>Strauss</surname><given-names>MT</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Leypoldt</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease</article-title>. <source>Mol Syst Biol</source>. (<year>2020</year>) <volume>16</volume>:<elocation-id>e9356</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.15252/msb.20199356</pub-id>
<pub-id pub-id-type="pmid">32485097</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dayon</surname><given-names>L</given-names></name><name><surname>Cominetti</surname><given-names>O</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name></person-group>. <article-title>Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications</article-title>. <source>Expert Rev Proteomics</source>. (<year>2022</year>) <volume>19</volume>:<page-range>131&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/14789450.2022.2070477</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torretta</surname><given-names>E</given-names></name><name><surname>Arosio</surname><given-names>B</given-names></name><name><surname>Barbacini</surname><given-names>P</given-names></name><name><surname>Capitanio</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>PD</given-names></name><name><surname>Moriggi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Novel insight in idiopathic normal pressure hydrocephalus (iNPH) biomarker discovery in CSF</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>8034</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ijms22158034</pub-id>
<pub-id pub-id-type="pmid">34360799</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>PS</given-names></name><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Catho</surname><given-names>G</given-names></name><name><surname>Blanchard-Rohner</surname><given-names>G</given-names></name><name><surname>Schiess</surname><given-names>N</given-names></name><name><surname>Cohrs</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Meningitis caused by the live varicella vaccine virus: metagenomic next generation sequencing, immunology exome sequencing and cytokine multiplex profiling</article-title>. <source>Viruses</source>. (<year>2021</year>) <volume>13</volume>:<elocation-id>2286</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/v13112286</pub-id>
<pub-id pub-id-type="pmid">34835092</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chapman</surname><given-names>J</given-names></name></person-group>. <article-title>Coagulation in inflammatory diseases of the central nervous system</article-title>. <source>Semin Thromb Hemost</source>. (<year>2013</year>) <volume>39</volume>:<page-range>876&#x02013;80</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1055/s-0033-1357482</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shavit-Stein</surname><given-names>E</given-names></name><name><surname>Aronovich</surname><given-names>R</given-names></name><name><surname>Sylantiev</surname><given-names>C</given-names></name><name><surname>Gera</surname><given-names>O</given-names></name><name><surname>Gofrit</surname><given-names>SG</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Blocking thrombin significantly ameliorates experimental autoimmune neuritis</article-title>. <source>Front Neurol</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>1139</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fneur.2018.01139</pub-id>
<pub-id pub-id-type="pmid">30662428</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weisfelt</surname><given-names>M</given-names></name><name><surname>Determann</surname><given-names>RM</given-names></name><name><surname>de Gans</surname><given-names>J</given-names></name><name><surname>van der Ende</surname><given-names>A</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Procoagulant and fibrinolytic activity in cerebrospinal fluid from adults with bacterial meningitis</article-title>. <source>J Infect</source>. (<year>2007</year>) <volume>54</volume>:<page-range>545&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jinf.2006.11.016</pub-id>
</mixed-citation></ref></ref-list></back></article>